Skip to main content

Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine

Buy Article:

$68.00 + tax (Refund Policy)

Apolipoprotein-derived peptides have emerged as a potential candidate for the treatment of various inflammatory disease conditions. These peptides bind to pro-inflammatory lipids and inhibit their inflammatory functions. Lysophosphatidylcholine (LPC) is a potent pro-inflammatory lipid and increased level of circulating LPC plays a major role in various acute and chronic inflammatory conditions. In this report we examined the effect of peptides derived from the C-terminal domain of human apolipoprotein E on the properties of LPC. Our results show that the peptides (E8, E10 and E11) bind to LPC and inhibit LPC-induced up-regulation of pro-inflammatory markers in human leukocytes. The results suggest that these peptides can be used as an anti-inflammatory agent in inflammatory conditions in which increased level of LPC is a culprit.

Keywords: Apolipoprotein-derived peptide; circular dichroism; fluorescence spectroscopy; inflammation; lysophosphatidylcholine; qRT-PCR

Document Type: Research Article

Publication date: 01 February 2014

More about this publication?
  • Protein & Peptide Letters publishes short papers in all important aspects of protein and peptide research, including structural studies, recombinant expression, function, synthesis, enzymology, immunology, molecular modeling, drug design etc. Manuscripts must have a significant element of novelty, timeliness and urgency that merit rapid publication. Reports of crystallisation, and preliminary structure determinations of biologically important proteins are acceptable. Purely theoretical papers are also acceptable provided they provide new insight into the principles of protein/peptide structure and function.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content